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Background: Non-compliance with antidepressant treatment continues to be a complex problem in mental health
care. In immigrant populations non-compliance is one of several barriers to adequate management of mental
illness; some data suggest greater difficulties in adhering to pharmacological treatment in these groups and an
increased risk of therapeutic failure.
The aim of this study is to assess differences in the duration and compliance with antidepressant treatment among
immigrants and natives in a Spanish health region.
Methods: Population-based (n = 206,603), retrospective cohort study including all subjects prescribed ADT between
2007 and 2009 and recorded in the national pharmacy claims database. Compliance was considered adequate
when the duration was longer than 4 months and when patients withdrew more than 80% of the packs required.
Results: 5334 subjects (8.5% of them being immigrants) initiated ADT. Half of the immigrants abandoned treatment
during the second month (median for natives = 3 months). Of the immigrants who continued, only 29.5% presented
good compliance (compared with 38.8% in natives). The estimated risk of abandoning/ending treatment in the
immigrant group compared with the native group, adjusted for age and sex, was 1.28 (95%CI 1.16-1.42).
Conclusions: In the region under study, immigrants of all origins present higher percentages of early
discontinuation of ADT and lower median treatment durations than the native population. Although this is a
complex, multifactor situation, the finding of differences between natives and immigrants in the same region
suggests the need to investigate the causes in greater depth and to introduce new strategies and interventions in
this population group.Background
Non-compliance with prescribed antidepressant treat-
ment (ADT) is one of the main problems in the manage-
ment of depression. Though it is unanimously
recommended that this treatment should be continued
after the acute phase to reduce the risk of relapse, the re-
search conducted to date reveals a high percentage of
early drop-out and low adherence to treatment [1,2]. In
our environment, a recent 5-year follow-up study of* Correspondence: icruzesteve@gmail.com
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reproduction in any medium, provided the or7525 patients found that 56% abandoned treatment dur-
ing the first four months and that only 22% maintained
satisfactory adherence after this period [3].
With the huge increase in worldwide migratory move-
ments in the last decade, the health of the immigrant
population has become a matter of growing concern to
health authorities. Mental health in particular has be-
come a priority study objective in this population, since
it is broadly accepted that migration is a stress factor
which may lead to the development of psychiatric illness.
Adequate management of mental illness is made espe-
cially difficult in this population by a number of factors:
the limited access to psychiatric care, the difficulty of
diagnosis due to cultural differences such as low rates of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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standing and acceptance of the therapy prescribed. To
date, few studies have compared adherence to ADT in
natives and immigrants; most of the data available on
this issue come from the analysis of factors associated
with non-compliance in general.
In Spain, the public health system guarantees access
and partial pharmacy coverage for all residents registered
in the census, of which immigrants comprise 12.2%
(1 January 2010) [4]. Nonetheless, we hypothesized that
immigrants would have greater difficulties in adhering to
treatment than natives and that the risk of treatment fail-
ure would be higher in the more vulnerable groups.
We decided to examine the possible differences be-
tween natives and immigrants with regard to the dur-
ation and adherence to prescribed ADT.
Methods
The study was performed in the health region of Lleida
(Spain), a region with an active population of 206,603
people between the ages of 15 and 64 years according to
the central national health insurance registry in 2007. This
registry includes all residents who are on the census list
of a municipality in the region. In 2007 foreigners repre-
sented 13.5% of residents recorded in the census. Most of
these foreigners were economic migrants from Eastern
Europe, the Maghreb, Latin America, Sub-Saharan Africa
and elsewhere.
Study population: population-based retrospective co-
hort of all subjects aged between 15 and 64 years pre-
scribed treatment with antidepressant drugs between 1
January 2007 and 31 December 2009.
The study included all individuals in the region who
had received at least one pack of antidepressants in 2007
but who had not received antidepressants in the previous
12 months. Subjects who had received ADT with ami-
triptyline alone were excluded, because of the habitual
use of this drug in the treatment of other pathologies
such as neuropathic pain or migraine. Individuals who
moved to other regions or who died were also excluded
from the analysis.
For each individual, age in 2007, sex, country of origin,
units of antidepressants from the NO6A subgroup in the
ATC classification system [5] dispensed at pharmacies,
the active ingredient, and month and year of dispensa-
tion were recorded.
The sociodemographic data were obtained from the
Primary Care Information System. Data on exposure to
drugs were obtained from the regional claims database.
In Spain the public health system pays 90% of the price
of antidepressant drugs officially prescribed to the popu-
lation with statutory health insurance. Information on
the packs dispensed per person is recorded in an individ-
ual database for each health region. We combined theinformation from these two databases using a common
personal identifier; the information was then treated an-
onymously in the subsequent analysis.
For this study, immigrants were defined as those from
low or middle-income countries according to the classifi-
cation of the World Bank based on per capita GDP [6].
If the country of origin was unknown, only those
recorded in the central insurance registry before 1
January 2003, when the percentage of immigrants in
the country was below 5%, were considered as natives.
Otherwise, subjects whose country of origin was un-
known were excluded from the study. The immigrants
were grouped according to area of origin into Eastern
Europe, Maghreb, Sub-Saharan Africa, Latin America,
and Others.
Treatment duration was calculated for each patient as
the number of months between the first dispensation in
2007 and the last during the study period. If patients did
not withdraw medication during a period of six con-
secutive months this was considered as the end of the
episode. Discontinuations of below six months, on the
other hand, were included in the duration of the epi-
sode. If a patient had presented more than one episode
during the study period, only the first one was included.
Treatment duration for patients who had not completed
treatment by the end of follow-up was considered as
censored.
The use of the terms “adherence” and “compliance”
was discussed by the research team and standardized. In
the literature, the terms are often used interchangeably
and the definitions used by different authors do not al-
ways coincide. Although in general the use of the term
adherence is preferred because of its connotation of vol-
untary cooperation, in this case we define them as
follows.
Treatment adherence was defined on the basis of the
medication possession ratio. For each antidepressant the
number of units per month that a patient needed accord-
ing to the daily dose defined by the WHO Collaborating
Centre for Drugs Statistics Methodology was recorded.
On this basis, the ratio between the number of units
obtained at the pharmacy and the theoretical number of
units required according to the duration of the episode
was obtained. Ratios of adherence above 80% were con-
sidered adequate.
By consensus, compliance was considered to be ad-
equate in patients with a treatment duration of more
than four months and an adherence of more than 80%
until the end of treatment.
The cohort’s characteristics with respect to the vari-
ables analysed were expressed as frequencies and percen-
tages. The distribution of treatment duration was
expressed by the means, medians, 25th and 75th percen-
tiles and 95% confidence intervals (95%CI).
Table 2 Characteristics of patients who only received
treatment for the first month with regard to sex, age and
origin, compared with patients who remained in
treatment more than one month
Treatment duration p
1 month >1 month
N 2013 3321
Male 35.9% 33.8% 0.116 (2)
Mean age (years) 45.5 46.2 0.064 (1)
IMMIGRANTS 10.8% 7.0% <=0.001 (2)
*Latin America 33.2% 36.3% 0.315 (2)
Eastern Europe 35.5% 37.6%
Maghreb 23.0% 22.2%
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function were estimated using the Kaplan-Meier method.
The survival curves were compared between groups using
the Log-Rank test. To determine which factors were related
to the treatment duration and the risk of abandonment/
completion, a Cox multivariate model was applied. This
model was used to estimate the hazard ratios (HR) and their
corresponding 95%CI of ending/abandoning treatment. The
same model was used to estimate the adjusted survival
curves. The analysis of treatment duration was performed
for the entire patient cohort and also for the subsample that
completed the first month of treatment. P values below 0.05
were considered statistically significant.
This study was approved by the Ethical Committee
of Clinical Research of the IDIAP J Gol (Primary Care
Research Institute, Spain).Sub-Saharan 7.4% 3.0%
Others 0.9% 0.9%
* Calculated using only the subgroup considered as immigrants.
(1) p value of the t-test (comparison of means).
(2) p value of the chi square independence test.Results
Description of samples
In 2007, 5,334 subjects began treatment with AD, that is,
2.58% of the population of the health region (1.37% of the
immigrant population and 2.81% of the natives). Of the
patients who began treatment, 91.5% were natives and 8.5%
immigrants. The distributions by area of origin and age
group are shown in Table 1.Duration of AD treatment
Of all the patients who began ADT in the study period,
37.7% (2013) withdrew medication only during the first
month of follow-up (48.1% of immigrants compared with
36.8% of natives).
The characteristics of the patients who abandoned treat-
ment during the first month (early discontinuation) were
compared with the continuers (Table 2). The percentage of
immigrants in the early discontinuation group was higher
than in the group that continued beyond this period, with
statistically significant differences.Table 1 Distribution of age in the sample according to
area of origin.
Age groups in years (%) Total
(n)15-24 25-34 35-44 45-54 55-64
NATIVES 8.2 17.6 24.3 25.5 24.4 4883
IMMIGRANTS 12.2 42.1 28.2 11.8 5.8 451
Latin America 10.8 35.0 31.2 16.6 6.4 157
Eastern Europe 16.4 46.1 24.8 7.9 4.8 165
Maghreb 9.8 44.1 26.5 11.8 7.8 102
Sub-Saharan Africa 0 60.9 30.4 8.7 0 23
Others 25.0 0 75.0 0 0 4Treatment duration for each group is shown in Table 3
and the survival functions in Figure 1. The differences
between natives and immigrants of all origins were sta-
tistically significant.
Half of the immigrants completed two months of treat-
ment, while half of the natives obtained medication for
three months (95%CI of the median = 2.7-3.3). Of the im-
migrant groups, the Sub-Saharan Africans and Others
presented the lowest median durations (one month).
Excluding the patients who abandoned during the first
month, the median duration was nine months (95%CI
8.5-9.5): six months for the immigrants (95%CI 4.9-7)
and nine months for the natives (95%CI 8.5-9.5). The dif-
ferences between natives and immigrants remained sta-
tistically significant.Table 3 Distribution of treatment duration by area of
origin
Median* P25 P75 Mean* 95%CI
NATIVES 3 13 1 11.1 10.7 11.5
IMMIGRANTS 2 6 1 6.4 5.5 7.4
Latin America 2 6 1 7.3 5.5 9.0
Eastern Europe 2 6 1 5.8 4.5 7.0
Maghreb 2 4 1 6.0 4.0 8.0
Sub-Saharan 1 9 1 4.6 1.9 7.3
Others 1 4 1 7 0.0 16.9
TOTAL 3 12 1 10.7 10.4 11.1
*Parameters calculated with the Kaplan-Meier method.
Figure 1 Survival function of treatment duration adjusted for age and sex using a Cox regression model.
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est in the 35-54 years age group; in this age group, median
duration was higher in the natives than in the immigrants.
Survival analysis using Cox regression estimated a risk
of abandoning/ending treatment in the immigrant group
vs. the native group of 1.28 (95%CI = 1.16-1.42), adjusted
for age and sex.Percentage of medication acquired
In all, 76.2% of patients were dispensed at least 80% of
the required medication.
Excluding the patients who abandoned during the first
month (one package for one month, 100% of required
medication dispensed), 59.7% of patients adhered to treat-
ment. No statistically significant differences were found
between natives and immigrants with regard to adherence.Compliance with treatment
In the whole sample, only 23.8% of patients who began
AD treatment remained compliant for a minimum of
four months and at the same time acquired more than
80% of the number of packs prescribed (15.3% of immi-
grants compared with 24.6% of natives, p <0.001).
When we excluded the patients who abandoned during
the first month, good compliance increased to 38.2%
(29.5% in immigrants and 38.8% in natives). There wereno significant differences between the areas of origin of
the immigrants.
Table 4 shows the percentage of compliant patients
according to sex, age and origin in the group of patients
who continued in treatment for a minimum of a month.Discussion
Main results
Our results show that half of the immigrant patients
who begin treatment with AD obtain medication for only
two months, compared with a median of three months
in the native group. The average risk of abandoning
treatment during follow-up is 28% higher in immigrant
patients than in the natives, adjusting for age and sex.
Of the patients who continued treatment beyond the
first month, only 29.5% of immigrants presented good
compliance, compared with 38.8% of natives (withdrawal
of above 80% of prescribed medication over at least four
months).
These rates fall well below the current recommenda-
tions of European and US scientific societies which indi-
cate the initiation of ADT in moderate or severe
episodes of depression, and prolongation of treatment
during the acute phase (between four and eight weeks)
with an additional period of four to nine months to pre-
vent relapses and to recover normal psychosocial func-
tions. Duration may be longer if the clinical history of
Table 4 Percentage of compliant patients according to
sex, age and origin
Compliant patients P
Male 36.5 0.151
Female 39.0
Age
15-24 years 24.6 <0.001
25-34 years 35.0
35-44 years 39.2
45-54 years 40.9
55-64 years 41.4
NATIVE 38.8 0.005
IMMIGRANT 29.5
Latin America 31.8 0.62
Eastern Europe 25.0
Maghreb 32.7
Sub-Saharan 42.8
Others 0
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duration of six months is recommended.Comparison with other published studies
Early abandonment of ADT is a well-documented, per-
sistent occurrence in spite of attempts to encourage ad-
herence. The percentages of abandonment during the
first month published in previous studies are similar to
ours, with figures ranging between 33% and 42% [1,7-
9]. As regards the duration of antidepressant treatment,
a study performed with a similar methodology [10] cor-
roborates our data since it obtained a median treatment
duration of three months, which the authors attributed
to the high percentage of early abandonment. Other
percentages of treatment abandonment published range
between 50% during the first three months [11], 62.4%
at the end of the third month [1] and 44% at six months
[12]. An earlier study in our region obtained a discon-
tinuation rate of 56% during the first four months [3].
Much less is known about the pattern of use of ADT
by the immigrant population. Most of the data recorded
are indirect and come from studies not specifically aimed
at this population or studies that do not conduct com-
parisons with natives. Van Geffen et al. [13] concluded
that the risk of not starting treatment or of acquiringonly one prescription is higher when the indication is
not specific, and that the risk of early abandonment is
five times higher in some immigrant groups than in
natives. Van Dijk et al. [14] found a relation between the
risk of abandonment of ADT and immigrant status, the
type of drug prescribed, and comorbidity. Hasen et al.
[7] associated early abandonment with foreign citizen-
ship, low educational level, and low income, and Olfson
et al. [1] related abandonment in the first 30 days with
being Hispanic, low educational level, and low family
income.
Our study provides evidence that immigrants of all ori-
gins present higher percentages of early discontinuation
of ADT and lower median treatment durations than the
native population in our health region, regardless of their
geographic origin. These findings corroborate those of a
previous study by our group that showed a lower expos-
ure to ADT in immigrants than in the native population;
this tendency was found in all the ethnic groups, but was
particularly marked in the sub-Saharans [15].
Although the study was not designed to analyse the
causes of the differences between the two populations,
the results oblige us to reflect on the factors that may
contribute to this situation and to assess whether these
differences indicate inequalities in health care.
Clearly, some of the factors associated with poor ad-
herence will affect both immigrants and natives and
therefore should be considered in the global strategy for
preventing non-compliance in all patients. However, in
the immigrant population, in which the economic, social
and family situations tend to be less favourable, factors
associated with socioeconomic status and environment
are likely to predominate. The measures for preventing
non-adherence, then, go beyond the jurisdiction of the
health system and need to be addressed at the broader
level of social and economic policy. Non-adherence due
to the cost of medication, a common finding in studies
in the US comparing white elderly with their black or
Hispanic peers [16], can be included in this group. In
Spain the public health system offers pharmaceutical
coverage for AD, under which patients pay only 10% of
the total cost, a situation that minimizes (but does not
eliminate entirely) this effect.
With respect to the factors associated with immigrant
status, it might be hypothesized that the shorter duration
of ADT and the lower rates of compliance were due in
part to a diagnostic bias. Incorrect diagnosis might lead
to ineffective prescription and to early drop-out due to
the lack of improvement. We cannot test this hypothesis
because we do not have information on the diagnoses
made. Nonetheless, the difficulties involved in diagnosing
psychiatric syndromes in populations from different cul-
tures are well known, due both to the barriers in com-
munication and to the possible unreliability of the
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DSM-IV in these populations.
The beliefs, expectations and attitudes towards mental
illness that form part of the cultural background of each
ethnic group should also be taken into consideration.
They may be very different from those of the host society
and may well affect adherence to pharmacological and
non-pharmacological treatments.
Most authors agree that patients’ attitude towards ADT
is one of the strongest predictors of adherence. Aikens
et al. found that subjects of advanced age, with more se-
vere symptoms, greater acceptance of the biochemical
cause of the illness and expectations of persistence of the
symptoms were more likely to perceive the need for treat-
ment; these authors also found that patients who had
never received AD treatment and who were not certain of
the cause of their symptoms were more likely to associate
therapy with negative effects [17]. Van Geffen et al. inter-
viewed patients in the early stages of ADT; those who
dropped out were less involved in decision-making, had
less faith in their doctor, reported a lack of information
and presented a negative attitude to ADT, and were not
convinced of the necessity of taking it [18]. Reviewing
studies of the differences in treatment of depressive and
anxiety disorders in ethnic minorities, Schraufnagel et al.
detected several obstacles to appropriate treatment, such
as the beliefs about treatment mentioned above, stigma,
the inability of the doctor to motivate the patient and the
biological differences that condition the treatment. None-
theless, these authors conclude that if the treatment is ad-
equate the results in minorities are comparable to those
achieved in the native population [19].
Finally, in relation to these results, it should be recalled
that health professionals may lack the intercultural compe-
tence necessary to provide optimal treatment to their
patients. Their unfamiliarity with their patient’s culture
may present a serious obstacle to early diagnosis and to
the development of the therapeutic alliance, both of which
are indispensable for obtaining positive results.
All things considered, the cultural identities of immi-
grant patients and their previous experiences of mental ill-
ness are likely to affect their ability to understand, accept
and believe in the benefits of treatment. This hurdle
appears to be especially significant in certain groups such
as the sub-Saharan Africans, the population with the low-
est median treatment duration and the lowest overall ex-
posure to ADT reported in the studies mentioned above,
and a lower exposure to antipsychotics than the rest of the
minorities [20].
These findings have serious implications for the care of
immigrant patients: implications for the use and
provision of health services (i.e., the need to reach mi-
grant groups considering the cultural specificity of each
of them, especially in early stages of treatment of mentalillness), implications for health policy (i.e., identifying the
factors that limit access to mental health services) and
implications for future research (i.e., analysing in depth
the causes of the differences observed).Limitations
The main limitations of the study are to do with the sample
selection. The sample is not representative of the entire im-
migrant population in the region, only of the immigrants
who appear in the municipal census. Furthermore, exposure
to ADT is estimated on the basis of medication withdrawn
from the pharmacies in the region, with the result that any
medication obtained in another health region is not
reflected; however, this situation would affect a minimal
number of cases in both groups, as the active population
recorded in the regional health register remained stable over
the period of analysis. The amounts of ADT received over
the counter were also considered to be minimal, as pre-
scriptions for this kind of drug are obligatory.
We are aware that our use of the concept of immigrant is
excessively general. Although we sought to distinguish be-
tween immigrant groups according to their geographical
origin, this approach also ignores the existence of differ-
ences between countries, between ethnic groups inside the
same country and between individuals in the same ethnic
group. For this reason, on the basis of these general data it
would be interesting to focus on those groups in which the
greatest differences were found with respect to the general
population.
The lack of diagnoses is a limitation inherent to many
studies performed on the basis of claims databases, since
this method does not identify the reason for the prescrip-
tion or the reason for the ending of treatment (i.e., cure or
abandonment). This means that the data should be inter-
preted with care. Similarly, the analysis of drugs dispensed
does not indicate the use that patients make of this medica-
tion, but reflects the intention to comply with treatment;
even so, most authors agree that dispensation is the best
measurement of medication use in large populations in ha-
bitual clinical practice.
Another limitation is the fact that we were unable to de-
termine primary non-compliance, that is, the number of
patients who are prescribed ADT but do not acquire the
first pack. This information should be added to the per-
centage of non-compliance detected, but at the time of the
study we did not have the prescription data needed to
carry out this estimation.
For the same reason, we were unable to check the dose of
ADT prescribed. We assumed that the daily dose prescribed
corresponded to the definitions of the WHO Collaborating
Centre for Drug Statistics Methodology, and that the pre-
scribing physicians followed the recommendations of this
institution.
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In this health region in Spain, half of the immigrant
patients who began ADT dropped out during the second
month of treatment.
Of the half that continued, only one of every three
obtained more than 80% of the packs prescribed in a mini-
mum period of four months, in spite of the current recom-
mendations in favour of longer treatments. Some
immigrant groups such as sub-Saharan Africans present
even shorter durations of treatment. This situation seems to
reflect an inadequate provision of mental health care in this
population.
Few studies of the prevalence of mental illness and adher-
ence to ADT have been performed in immigrant groups in
our environment. Since the objective of the Spanish na-
tional health system is to guarantee an equitable provision
of care, it is vital to attend to the needs of the immigrant
population and to ensure adequate access and use of health
services. To achieve this aim, we need valid data from stud-
ies that are specifically designed to detect immigrants’ needs
and propose appropriate responses. These studies should
not only provide quantitative data but should also include
qualitative methodologies to explore the immigrant
perspective.
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